EHRA 25: The MORE-CRT MPP Trial: Cardiac Resynchronization Therapy with MultiPoint Pacing

6 Views
Published
EHRA 2025 - Outcomes from cardiac resynchronization therapy (CRT) with MultiPoint pacing (MPP) to treat patients who are not responding to standard CRT show that MPP does not improve the conversion rate of non-responders to responders compared to standard CRT; however, a reduction in HF hospitalisation was seen in the group receiving MPP.

Prof Christophe Leclercq (Centre Hospitalier Universitaire of Rennes, Rennes, FR) joins us on-site at EHRA Congress 2025 to discuss the prospective, randomized, multi-center MORE-CRT MPP trial (NCT02006069; Abbott Medical Devices). MORE-CRT MPP aimed to assess whether CRT with an MPP device for patients who did not respond to standard CRT could improve the conversion rate of non-responders to responders compared to standard CRT.

Interview Questions:
1. Could you tell us about the unique features of the MPP device?
2. What is the importance behind the MORE-CRT MPP trial?
3. What was the study design and patient population?
4. What were the key findings and how can they be used to identify patients who would benefit most from CRT with MPP?
5. What are the take-home messages for practice?
6. What further research is needed in this area?

Recorded on-site at EHRA in Vienna, 2025.

Editors: Yazmin Sadik, Jordan Rance
Videographers: Tom Green, Oliver Miles
Support: This is an independent interview produced by Arrhythmia Academy.

Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: https://www.facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO
Category
Cardiology
Be the first to comment